Company intelligence / Profile preview

Angiocrine Bioscience

San Diego, California, United Statesangiocrinebioscience.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 3

Overview

Currently conducting a Phase 3 double-blind, randomized, placebo-controlled study (E-CELERATE) to evaluate the efficacy and safety of AB-205 plus standard of care versus placebo in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation. Previous Phase 1/2 study showed AB-205 was well tolerated with only 9% incidence of early oral/GI SRRT compared to 41% in a contemporary observational study.

Therapeutic areas: GastroenterologyImmunologyOtherOncologyNeurology
Modalities: Engineered Cell TherapyGene TherapyStem Cell Therapy
Industry: Biotech

Drug pipeline

3 assets

E-CEL UVEC

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Angiocrine Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiocrine Bioscience.

Explore the full profile